“The legacy of the South African Medical Research Council’s contribution to research and investments in HIV prevention strategies is world-renowned,” said Dr. James Kublin, the HVTN’s executive director.
“The MRC, as the research council constituted to address pressing health needs of South African citizens and a leader in developing sub-type C HIV vaccines, is the obvious partner for this endeavor,” said Glenda Gray, director of the Office of AIDS Research at the MRC and the HVTN’s co-principal investigator.
Gray is charged with the HVTN’s expansion into southern Africa and will lead an upcoming phase 3 HIV vaccine licensure study in South Africa. She is surrounded by many talented scientists who include the world-renowned adolescent expert and HIV prevention specialist Linda Gail Bekker; Gavin Churchyard, a clinical epidemiologist and physician with expertise in clinical trials design and tuberculosis; as well as emerging scientific leaders such as Drs. Fatima Laher, Surita Roux and Kathy Ngadi.
“To be partners with the MRC in these future HIV vaccine clinical trials is a testament to South Africa’s commitment to finding an HIV vaccine,” said Larry Corey, president of Fred Hutch and the HVTN’s principal investigator.
The HVTN, together with local partners such as the MRC and South African universities, is committed to continue to grow the existing HIV vaccine research expertise in South African. Through the South African/HVTN AIDS Vaccine Early Stage Investigator Programme (SHAPe), which provides mentoring and funding to young South African physicians interested in careers in HIV research, the program will build the next generation of researchers needed to conduct HVTN studies in South Africa.
South African researchers conducted the first study to show that a topical microbicide gel could reduce the risk of contracting HIV. Conducted by Dr. Karim at the CAPRISA site, the study involved close to 900 women between 2007 and 2009 and found that those who used tenofovir gel had 39 percent fewer HIV infections than women who received a placebo gel.
Beyond its collaboration with the HVTN, the South African government has made strides in recent years to combat the nation’s HIV epidemic. According to UNAIDS, an estimated 6.1 million South Africans – more than 10 percent of the population – are currently living with HIV. The rates are highest among women aged 15 to 24, who are three times more likely to become infected as men in the same age group.
But the tide seems to be changing. Two years ago, the South African government launched a multipronged initiative to reduce HIV infection that includes testing and counseling, efforts to prevent mother-to-child transmission, education around prevention methods and promotion of male circumcision.
Rates of child HIV infection dropped by 63 percent in South Africa between 2009 and 2012, according to UNAIDS, and the nation now has the largest number of people worldwide – more than 1.4 million – enrolled in antiretroviral drug treatment.